1Seheen AJ, Paquot N. Metformin revisited : a critical review of the benefit-risk balance in at-~k patients with type 2 diabetes [ J ]. Diabetes Metab, 2013,39(3) :179-190.
3Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoproteetive efficacy [ J ]. J Renal Inj Prey, 2013,2(2) :35-36.
4Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy [ J ]. J Renal Inj Prey, 2013,2(1) :9-10.
5Sung JY, Choi HC. Metformin-induced AMP-activated protein ki- nase activation regulates phenylephrine-mediated contraction of rat aorta [ J ]. Biochem Biophys Res Commun, 2012,421 ( 3 ) : 599 -604.
6UK Prospective Diabetes Study (UKPDS) Group. Effect of inten- sive bland-glucose control with metformin on complications in over- weight patients with type 2 diabetes ( UKPDS 34) [ J]. Lancet, 1998,352(9131 ) :854-865.
7Nasri H. On the occasion of the world diabetes day 2013 ; diabetes education and prevention; a nephrology point of view[ J]. J Renal Inj Prey, 2013,2(2) :31-32.
8Cheung NW. The management of gestational diabetes [ J ]. Vase Health Risk Manag, 2009,5 ( 1 ) : 153-164.
9Balani J, Hyer SL, Rodin DA, et al. Pregnancy outcomes in women with gestational diabetes treated with mefformin or insulin: a case-control study [ J ]. Diabet Med, 2009,26 ( 8 ) :798-802.
10Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol ) for women with polycystie ovary syndrome, oligo amenorrhoea and subfertility[J]. Cochrane Database Syst Rev, 2009(4):CD003053.
